Biotech news

[Aeiou]

FDA Approves Bionovo's Clinical Development Plan for Menerba

 

[Zohar]

IPOfinancial.com Initiates Research Coverage of Rexahn Pharmaceuticals with a $4.00 Intermediate Term Price Target

 

[viralic]

Amarin Corporation plc (ADR) (NASDAQ:AMRN) rose 1% to $3.30 Today, analyst at Canaccord Genuity started a coverage on the stock with a Buy rating and set a $7 price target.

 

[Aeiou]

Oggi più di un grafico ha l'aspetto di una catenaria. Vedi AVNR, KERX, PSDV. Rapina ai polli o che altro?

 

[Aeiou]

Bionovo

Bionovo, Inc. to Present at the Maxim Group Growth Conference

 

[Zohar]

Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany - MarketWatch

 

[Zohar]

Aastrom Presents Positive Second Interim Analysis of Phase 2b RESTORE-CLI Clinical Trial - MarketWatch

 

[Zohar]

FDA approves Xgeva (denosumab) for oncology indication - FierceBiotech

 

[DickSIM]

Genzyme ($GENZ) restructuring moves forward with sale of diagnostic ops - FierceBiotech

 

[Zohar]

CEL-SCI Completes Global Investigator Meeting in Preparation for Enrollment and Treatment of Patients in Phase III Head and Neck Cancer Trial | Business Wire